TearLab Corporation Reports Fourth Quarter and Year End 2016 Financial Results
Mar 09, 2017 21:02 pm UTC| Business
SAN DIEGO, March 09, 2017 -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (“TearLab” or the “Company”) today reported its consolidated financial results for the fourth quarter and twelve months ended December 31, 2016....
TearLab Corporation Reports Fourth Quarter and Year End 2016 Financial Results
Mar 09, 2017 21:02 pm UTC| Business
SAN DIEGO, March 09, 2017 -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (“TearLab” or the “Company”) today reported its consolidated financial results for the fourth quarter and twelve months ended December 31, 2016....
Cara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
Mar 09, 2017 21:02 pm UTC| Business
STAMFORD, Conn., March 09, 2017 -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively...
Cara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
Mar 09, 2017 21:02 pm UTC| Business
STAMFORD, Conn., March 09, 2017 -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively...
NV5 Announces Record Fourth Quarter and Full Year Financial Results
Mar 09, 2017 21:02 pm UTC| Business
HOLLYWOOD, Fla., March 09, 2017 -- NV5 Global, Inc. (Nasdaq:NVEE) (“NV5” or the “Company”), a provider of professional and technical engineering and consulting solutions, today reported financial results for the fourth...
NV5 Announces Record Fourth Quarter and Full Year Financial Results
Mar 09, 2017 21:02 pm UTC| Business
HOLLYWOOD, Fla., March 09, 2017 -- NV5 Global, Inc. (Nasdaq:NVEE) (“NV5” or the “Company”), a provider of professional and technical engineering and consulting solutions, today reported financial results for the fourth...
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
Mar 09, 2017 21:02 pm UTC| Business
Top-Line Data for First Phase 3 Study Expected in 3Q 2017 ZX008 Phase 3 Pivotal Study 1504 Initiated – Target Data Readout by End of 2017 Planned Initiation of Phase 3 study of ZX008 in Lennox Gastaut Syndrome in 2H...